inovmedИнновационная медицина КубаниInnovative Medicine of Kuban2541-9897Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1inovmed-124Research ArticleОБЗОРЫREVIEWSСКРИНИНГ КОЛОРЕКТАЛЬНОГО РАКА. ОБЗОР СУЩЕСТВУЮЩИХ МЕТОДОВ И РЕКОМЕНДАЦИЙCOLORECTAL CANCER SCREENING. CURRENT TECHNIQUES AND RECOMMENDATIONS REVIEWПузановД. П.PuzanovD. P.dmitrii-puzanov@mail.ruПоловинкинВ. В.PolovinkinV. V.vvpolovinkin@gmail.ruПузановаИ. А.PuzanovaI. A.puzanova.inna.1985@mail.ruНаучно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского Министерства здравоохранения Краснодарского краяРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of HealthRussian FederationНаучно-исследовательский институт – Краевая клиническая больница № 1 им. проф. С.В. Очаповского Министерства здравоохранения Краснодарского края; Кубанский государственный медицинский университет Министерства здравоохранения РФРоссияScientific Research Institute – Ochapovsky Regional Clinical Hospital no. 1, The Krasnodar Krai Ministry of Health; Kuban State Medical University, Ministry of Health of the Russian FederationRussian Federation201830032018015864Copyright © Пузанов Д.П., Половинкин В.В., Пузанова И.А., 20182018Пузанов Д.П., Половинкин В.В., Пузанова И.А.Puzanov D.P., Polovinkin V.V., Puzanova I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.innovmedkub.ru/jour/article/view/124Цель

Цель. Обзор основных методов скрининга для выявления случаев заболеваемости колоректальным раком, анализ сходства и отличий.

Материал и методы

Материал и методы. Обзор скрининговых методов был произведен с помощью международных баз MEDLINE, EMBASE, SCOPUS, CENTRAL, ISI Web, Google и Google Scholar с опорой на опубликованные рекомендации Всемирной организации гастроэнтерологии. В большинстве руководств предлагается проведение скрининга у лиц в возрасте от 50 до 75 лет с проведением фиброколоноскопии каждые 10 лет или гибкой сигмоскопии каждые 5 лет и ежегодное проведение копротестов (биохимические тесты на обнаружение скрытой крови в кале). Отличия в руководствах связаны с последовательностью проведения исследований и интервалами проведения тестов.

Выводы

Выводы. Средний рекомендуемый возраст для проведения скрининга составляет от 50 до 75 лет; двухэтапный скрининг с проведением FIT-тестов на первом этапе и ФКС на втором является наиболее оптимальным вариантом скрининга.

Objective

Objective. The review of the main screening methods for identification of cases with colorectal cancer, and analyze differences and likeliness.

Materials and Methods

Materials and Methods. Review of the screening methods was performed by means of international bases MEDLINE, EMBASE, Scopus, Central, ISI Web, Google and Goggle Scholar and considering published recommendations of World Wide Organization of Gastroenterology. In most guidelines screening in patients, with mean age 50–75 years, is discussed, and performance of fibrocolonoscopy every 10 years or flexible sigmoidoscopy every 5 years and annual FOB test are recommended. Differences in guidelines may be referred to intervals between tests and consistency of performed tests.

Conclusion

Conclusion. Mean recommended age indicated for screening performance is 50–75 years; two-staged screening with FIT at first stage and FCS at second stage represent the most optimal screening pattern.

колоректальный ракскрининггемокульт-тестгваяковая пробаFITколоноскопияcolorectal cancerscreeninghemoccult testguaiac testFITcolonoscopyReferencesBénard F., Barkun A.N., Martel M. et al. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations. World J Gastroenterol. 2018; 24(1): 124-138.Bénard F., Barkun A.N., Martel M. et al. Systematic review of colorectal cancer screening guidelines for average-risk adults: Summarizing the current global recommendations. World J Gastroenterol. 2018; 24(1): 124-138.Zavoral M., Suchanek S., Majek O. et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol. 2014; 20(14): 3825-3834.Zavoral M., Suchanek S., Majek O. et al. Colorectal cancer screening: 20 years of development and recent progress. World J Gastroenterol. 2014; 20(14): 3825-3834.Woodall M., DeLetter M. Colorectal Cancer. A collaborative approach to improve education and screening in a rural population. Clinical Journal of Oncology Nursing. 2017; 22(14): 69-75.Woodall M., DeLetter M. Colorectal Cancer. A collaborative approach to improve education and screening in a rural population. Clinical Journal of Oncology Nursing. 2017; 22(14): 69-75.Bond J.H. Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Gastroenterol Clin North Am.1997; 26: 57-70.Bond J.H. Fecal occult blood testing for colorectal cancer. Can we afford not to do this? Gastroenterol Clin North Am.1997; 26: 57-70.Чиссов В.И., Сергеева Н.С., Зенкина Е.В., Маршутина Р.В. Эволюция копро-тестов в активном выявлении колоректального рака. РЖГГК. 2012; 22(6): 44-52.Чиссов В.И., Сергеева Н.С., Зенкина Е.В., Маршутина Р.В. Эволюция копро-тестов в активном выявлении колоректального рака. РЖГГК. 2012; 22(6): 44-52.Lindholm E., Brevinge H., Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br JSurg 2008; 95: 1029-1036.Lindholm E., Brevinge H., Haglind E. Survival benefit in a randomized clinical trial of faecal occult blood screening for colorectal cancer. Br JSurg 2008; 95: 1029-1036.Shaukat A., Mongin S.J., Geisser M.S. et al. Longterm mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-1114.Shaukat A., Mongin S.J., Geisser M.S. et al. Longterm mortality after screening for colorectal cancer. N Engl J Med. 2013; 369: 1106-1114.Elmunzer B.J., Hayward R.A., Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012; 9: 1352.Elmunzer B.J., Hayward R.A., Schoenfeld PS, et al. Effect of flexible sigmoidoscopy-based screening on incidence and mortality of colorectal cancer: a systematic review and meta-analysis of randomized controlled trials. PLoS Med. 2012; 9: 1352.Bacchus C.M., Dunfield L., Gorber S.C., et al. Recommendations on screening for colorectal cancer in primary care. CMAJ 2016; 188: 340-348.Bacchus C.M., Dunfield L., Gorber S.C., et al. Recommendations on screening for colorectal cancer in primary care. CMAJ 2016; 188: 340-348.Watson A.J., Collins P.D. Colon cancer: a civilization disorder. Dig Dis. 2011; 29: 222-228.Watson A.J., Collins P.D. Colon cancer: a civilization disorder. Dig Dis. 2011; 29: 222-228.Atkin W., Kralj-Hans I., Wardle J., et al. Colorectal cancer screening. Randomised trials of flexible sigmoidoscopy. BMJ. 2010; 341; 4618.Atkin W., Kralj-Hans I., Wardle J., et al. Colorectal cancer screening. Randomised trials of flexible sigmoidoscopy. BMJ. 2010; 341; 4618.Matsuda T. The Characteristics of Interval Cancers and Right-sited Lesions from the Japanese Perspective. WEO Colorectal Cancer Screening Committee Meeting, 2012.Matsuda T. The Characteristics of Interval Cancers and Right-sited Lesions from the Japanese Perspective. WEO Colorectal Cancer Screening Committee Meeting, 2012.Majek O., Gondos A., Jansen L., et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer. 2012; 106: 1875-1880.Majek O., Gondos A., Jansen L., et al. Survival from colorectal cancer in Germany in the early 21st century. Br J Cancer. 2012; 106: 1875-1880.Тимофеев Ю.М. Колоректальный рак: современные аспекты диагностики и лечения. РМЖ. 2004; 12(11): 653-656.Тимофеев Ю.М. Колоректальный рак: современные аспекты диагностики и лечения. РМЖ. 2004; 12(11): 653-656.Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med. 2004; 351: 2704-2714.Imperiale T.F., Ransohoff D.F., Itzkowitz S.H., et al. Fecal DNA versus fecal occult blood for colorectal cancer screening in an average-risk population. N Engl J Med. 2004; 351: 2704-2714.Burtonwood C., Butler P., Young M., et al. Monitoring faecal occult blood test positivity in the NHS Bowel Cancer Screening Programme // Gut. 2012. Vol. 61. P. 334.Burtonwood C., Butler P., Young M., et al. Monitoring faecal occult blood test positivity in the NHS Bowel Cancer Screening Programme // Gut. 2012. Vol. 61. P. 334.Imperiale T.F. Molecular markers - are they ready yet? WEO Colorectal Cancer Screening Committee Meeting, 2012.Imperiale T.F. Molecular markers - are they ready yet? WEO Colorectal Cancer Screening Committee Meeting, 2012.Meguro T. Measurement of fecal hemoglobin-haptoglobin complex as a new diagnostic tool of lower GIT diseases. Hokkaido Igaku Zasshi. 1994; 69(4): 995-1009.Meguro T. Measurement of fecal hemoglobin-haptoglobin complex as a new diagnostic tool of lower GIT diseases. Hokkaido Igaku Zasshi. 1994; 69(4): 995-1009.Seig A., Thoms C., Lüthens K., et al. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int. J. Colorectal Dis. 1999; 14(6): 267-271.Seig A., Thoms C., Lüthens K., et al. Detection of colorectal neoplasms by the highly sensitive hemoglobin-haptoglobin complex in feces. Int. J. Colorectal Dis. 1999; 14(6): 267-271.Karl J., Wild N., Tacke M. et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 2008; 6(10): 1122-1128.Karl J., Wild N., Tacke M. et al. Improved diagnosis of colorectal cancer using a combination of fecal occult blood and novel fecal protein markers. Clin. Gastroenterol. Hepatol. 2008; 6(10): 1122-1128.von Karsa L., Patnick J., Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Executive summary. Endoscopy 2012; 44 Suppl 3: 1-8.von Karsa L., Patnick J., Segnan N. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition-Executive summary. Endoscopy 2012; 44 Suppl 3: 1-8.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L., Patnick J., Segnan N., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013; 45: 51-59.European Colorectal Cancer Screening Guidelines Working Group, von Karsa L., Patnick J., Segnan N., et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication. Endoscopy. 2013; 45: 51-59.GGPO. Evidenced-based Guideline for Colorectal Cancer, long version 1.0. In: German Cancer Society [Internet]. Berlin: GGPO. 2014 Available at: http://www.awmf.org/fileadmin/user_upload/Leitlinien/021_D_Ges_fuer_Verdauungs-_und_Stoffwechselkrankheiten/021-007_S3_Colorectal_Cancer_2015_03-extended.pdfGGPO. Evidenced-based Guideline for Colorectal Cancer, long version 1.0. In: German Cancer Society [Internet]. Berlin: GGPO. 2014 Available at: http://www.awmf.org/fileadmin/user_upload/Leitlinien/021_D_Ges_fuer_Verdauungs-_und_Stoffwechselkrankheiten/021-007_S3_Colorectal_Cancer_2015_03-extended.pdfRex D.K., Boland C.R., Dominitz J.A., et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017; 112: 1016-1030.Rex D.K., Boland C.R., Dominitz J.A., et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017; 112: 1016-1030.Fang J.Y., Zheng S., Jiang B. et al. Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China. Gastrointest Tumors. 2014; 1: 53-75.Fang J.Y., Zheng S., Jiang B. et al. Consensus on the Prevention, Screening, Early Diagnosis and Treatment of Colorectal Tumors in China: Chinese Society of Gastroenterology, October 14-15, 2011, Shanghai, China. Gastrointest Tumors. 2014; 1: 53-75.WGO. Colorectal Cancer Screening. In: World Gastroenterology Organisation [Internet]. Milwaukee: World Gastroenterology Organisation. 2007 Available at: http://www.worldgastroenterology.org/UserFiles/file/ guidelines/colorectal-cancer-screening-english-2007.pdfWGO. Colorectal Cancer Screening. In: World Gastroenterology Organisation [Internet]. Milwaukee: World Gastroenterology Organisation. 2007 Available at: http://www.worldgastroenterology.org/UserFiles/file/ guidelines/colorectal-cancer-screening-english-2007.pdfThakkar J.P., McCarthy B.J., Villano J.L. Age-specific cancer incidence rates increase through the oldest age groups. Am J Med Sci. 2014; 348: 65-70.Thakkar J.P., McCarthy B.J., Villano J.L. Age-specific cancer incidence rates increase through the oldest age groups. Am J Med Sci. 2014; 348: 65-70.Lieberman D.A., Weiss D.G., Bond J.H. et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000; 343: 162-168.Lieberman D.A., Weiss D.G., Bond J.H. et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med. 2000; 343: 162-168.Day L.W., Velayos F. Colorectal cancer screening and surveillance in the elderly: updates and controversies. Gut Liver. 2015; 9: 143-151.Day L.W., Velayos F. Colorectal cancer screening and surveillance in the elderly: updates and controversies. Gut Liver. 2015; 9: 143-151.Quintero E., Castells A., Bujanda L et al. COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366: 697-706.Quintero E., Castells A., Bujanda L et al. COLONPREV Study Investigators. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med. 2012; 366: 697-706.Segnan N., Senore C., Andreoni B., et al. SCORE3 Working Group-Italy. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007; 132: 2304-2312.Segnan N., Senore C., Andreoni B., et al. SCORE3 Working Group-Italy. Comparing attendance and detection rate of colonoscopy with sigmoidoscopy and FIT for colorectal cancer screening. Gastroenterology. 2007; 132: 2304-2312.van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.van Rossum L.G., van Rijn A.F., Laheij R.J., et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90.

The authors declare that there are no conflicts of interest present.